Publicacións en colaboración con investigadores/as de Eli Lilly and Company (8)

2024

  1. Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain

    Advances in Therapy

  2. Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe

    Endocrine, Vol. 83, Núm. 3, pp. 585-593

  3. The Burden of Suboptimal Insulin Dosing in People with Diabetes in Spain: Barriers and Solutions from the Physician Perspective

    Patient Preference and Adherence, Vol. 18, pp. 151-164

  4. Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects

    Diabetes Therapy, Vol. 15, Núm. 7, pp. 1501-1512

2023

  1. Experience with the ENDMAP project, a training activity for Family Doctors in Endocrinology and Nutrition

    Atencion Primaria Practica, Vol. 5, Núm. 4

2021

  1. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

    The Lancet, Vol. 398, Núm. 10313, pp. 1811-1824

2002

  1. Características de la versión española del cuestionario de calidad de vida QLSM-H en sujetos adultos con deficiencia de hormona de crecimiento tratados con somatotropina. Estudio piloto

    Endocrinologia y Nutricion, Vol. 49, Núm. 4, pp. 105-112

1997

  1. Leptin inhibits in vitro hypothalamic somatostatin secretion and somatostatin mRNA levels

    Endocrinology, Vol. 138, Núm. 12, pp. 5641-5644